Author index

Abboud, L., Hir, J., Eisen, I. & Markiewicz, W. Exercise-induced symptomatic ischaemia predicts a poor long-term prognosis after acute myocardial infarction, 53
Adami, H.-O. *see* Kuper, H.
Adami, H.-O. *see* Tamimi, R.M.
Airaghi, L. *see* Tedeschi, A.
Allegri, L. *see* Vaglio, A.
Almroth, G., Ekermo, B., Månsson, A.-S., Svensson, G. & Widell, A. Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989–January 1997), 119
Alper, E. *see* Usta, M.
Anan, I. *see* Nyhlin, N.
Andersson, F.L. *see* Björholt, I.
Andersson, G. *see* Kärvestedt, L.
Ando, Y. *see* Nyhlin, N.
Andréasson, B. *see* Johansson, P.
Andrès, E., Noel, E. & Maloisel, F. Nonchemotherapy drug-induced agranulocytosis: interest of haematopoietic growth factors, 533
Asplund, K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review, 372
Asplund, K. *see* Lundberg, V.
Asselbergs, F.W. *see* van Haelst, P.L.
Aunola, S. *see* Marniemi, J.

van Baal, W.M. *see* Post, M.S.
Baldini, M., Gallazzi, M., Orsatti, A., Fossati, S., Leonardi, P. & Cantalamessa, L. Treatment of benign modular goiter with mildly supressive doses of L-thyroxine. Effects on bone mineral density and on nodule size, 407
Banga, J.D. *see* van Venrooij, F.V.
Bargero, G. *see* Veglio, M.
Basu, S. *see* Vessby, J.
de Beer, F., Smelt, A.H.M., van Vark, L.C., Hoogerbrugge, N., Havekes, L.M. & Gevers Leuven, J.A. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia, 148
Bell, H. *see* Dalgard, O.
Bengtsson, C. *see* Lindqvist, P.
Berg, K. *see* Os, I.
Berglund, G. *see* Norinder, A.
Berne, C. *see* Vessby, J.
Bhalla, A., Wolfe, C.D.A. & Rudd, A.G. Reply to Fotherby & Panayiotou, 179
Björholt, I., Andersson, F.L., Kahan, T. & Östergren, J. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study, 508
Björkelund, C. *see* Lindqvist, P.
Björntorp, P. *see* Rosmond, R.
Bjøro, K. *see* Dalgard, O.
Bjøro, T. *see* Dalgard, O.
Boffetta, P. *see* Kuper, H.
Borra, M. *see* Veglio, M.
Børvik, T. *see* Halvorsen, D.S.
Boström, S. *see* Lundberg, V.
Bouchard, C. *see* Rosmond, R.
Bouchard, C. *see* Ukkola, O.
Broman, J.-E. *see* Mallon, L.
Bruno, G. *see* Veglio, M.
Buzio, C. *see* Vaglio, A.

Cantalamessa, L. *see* Baldini, M.
Cavallo-Perin, P. *see* Veglio, M.
Ciceri, L. *see* Tedeschi, A.
Cohen Tervaert, J.W. *see* van Haelst, P.L.
Cohen, J. *see* Schattner, A.
Corradi, D. *see* Vaglio, A.

D'Errico, N. *see* Veglio, M.
Dalgard, O., Bjøro, K., Hellum, K., Myrvang, B., Bjøro, T., Haug, E. & Bell, H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy, 400
Delaval, D. *see* Després, J.-P.
Després, J.-P., Lemieux, I., Salomon, H. & Delaval, D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial, 490
Dilek, K. *see* Usta, M.
Diz-Lois, F. *see* de la Iglesia, F.
Djurovic, S. *see* Os, I.
van Doormaal, J.J. *see* van Haelst, P.L.

Efendic, S. *see* Kärvestedt, L.
Eisen, I. *see* Abboud, L.
Ek, A.-C. *see* Hollman, G.
Ekermo, B. *see* Almroth, G.
Eklund, A. *see* Planck, A.
El Salhy, M. *see* Nyhlin, N.
Elving, L.D. *see* Netea, R.T.
Emeis, J.J. *see* Post, M.S.
Eriksson, M. *see* Hollman, G.
Erkelens, D.W. *see* van Venrooij, F.V.
Ersoy, A. *see* Usta, M.

Felmeden, D.C. *see* Lee, K.W.
Ferrozzi, F. *see* Vaglio, A.
Filiz, G. *see* Usta, M.
Fletcher, L.M. & Halliday, J.W. Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism, 181
Forsblad, J. *see* Gottsäter, A.
Fossati, S. *see* Baldini, M.
Fotherby, M.D. & Panayiotou, B.N. Twenty-four hour blood pressure following stroke, 179
Frykman, V. Reply to Jolobe, 365
Fujimura, Y. *see* Orimo, S.

Gallazzi, M. *see* Baldini, M.
Gans, R.O.B. *see* van Haelst, P.L.
Gevers Leuven, J.A. *see* de Beer, F.
Giannini, S. *see* Tedeschi, A.
Gilad, A. *see* Schattner, A.
Giner, V., Muñoz, R. & Redón, J. Risperidone and severe cerivastatin-induced rhabdomyolysis, 177
Gisslén, K., Wieslander, J., Westberg, G. & Herlitz, H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis, 129
Gottsäter, A., Forsblad, J., Mätzsch, T., Persson, K., Ljungcrantz, I., Ohlsson, K. & Lindgärde, F. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and *Chlamydia pneumoniae* IgA antibodies, 61
Grill, V. *see* Kärvestedt, L.
Grobbee, D.E. *see* van Venrooij, F.V.
Grunewald, J. *see* Planck, A.

© 2002 Blackwell Science Ltd

Author index

Abboud, L., Hir, J., Eisen, I. & Markiewicz, W. Exercise-induced symptomatic ischaemia predicts a poor long-term prognosis after acute myocardial infarction, 53
Adami, H.-O. *see* Kuper, H.
Adami, H.-O. *see* Tamimi, R.M.
Airaghi, L. *see* Tedeschi, A.
Allegri, L. *see* Vaglio, A.
Almroth, G., Ekermo, B., Månsson, A.-S., Svensson, G. & Widell, A. Detection and prevention of hepatitis C in dialysis patients and renal transplant recipients. A long-term follow up (1989–January 1997), 119
Alper, E. *see* Usta, M.
Anan, I. *see* Nyhlin, N.
Andersson, F.L. *see* Björholt, I.
Andersson, G. *see* Kärvestedt, L.
Ando, Y. *see* Nyhlin, N.
Andréasson, B. *see* Johansson, P.
Andrès, E., Noel, E. & Maloisel, F. Nonchemotherapy drug-induced agranulocytosis: interest of haematopoietic growth factors, 533
Asplund, K. Antioxidant vitamins in the prevention of cardiovascular disease: a systematic review, 372
Asplund, K. *see* Lundberg, V.
Asselbergs, F.W. *see* van Haelst, P.L.
Aunola, S. *see* Marniemi, J.

van Baal, W.M. *see* Post, M.S.
Baldini, M., Gallazzi, M., Orsatti, A., Fossati, S., Leonardi, P. & Cantalamessa, L. Treatment of benign modular goiter with mildly supressive doses of L-thyroxine. Effects on bone mineral density and on nodule size, 407
Banga, J.D. *see* van Venrooij, F.V.
Bargero, G. *see* Veglio, M.
Basu, S. *see* Vessby, J.
de Beer, F., Smelt, A.H.M., van Vark, L.C., Hoogerbrugge, N., Havekes, L.M. & Gevers Leuven, J.A. The effect of tibolone on the lipoprotein profile of postmenopausal women with type III hyperlipoproteinemia, 148
Bell, H. *see* Dalgard, O.
Bengtsson, C. *see* Lindqvist, P.
Berg, K. *see* Os, I.
Berglund, G. *see* Norinder, A.
Berne, C. *see* Vessby, J.
Bhalla, A., Wolfe, C.D.A. & Rudd, A.G. Reply to Fotherby & Panayiotou, 179
Björholt, I., Andersson, F.L., Kahan, T. & Östergren, J. The cost-effectiveness of ramipril in the treatment of patients at high risk of cardiovascular events: a Swedish sub-study to the HOPE study, 508
Björkelund, C. *see* Lindqvist, P.
Björntorp, P. *see* Rosmond, R.
Bjøro, K. *see* Dalgard, O.
Bjøro, T. *see* Dalgard, O.
Boffetta, P. *see* Kuper, H.
Borra, M. *see* Veglio, M.
Børvik, T. *see* Halvorsen, D.S.
Boström, S. *see* Lundberg, V.
Bouchard, C. *see* Rosmond, R.
Bouchard, C. *see* Ukkola, O.
Broman, J.-E. *see* Mallon, L.
Bruno, G. *see* Veglio, M.
Buzio, C. *see* Vaglio, A.

Cantalamessa, L. *see* Baldini, M.
Cavallo-Perin, P. *see* Veglio, M.
Ciceri, L. *see* Tedeschi, A.
Cohen Tervaert, J.W. *see* van Haelst, P.L.
Cohen, J. *see* Schattner, A.
Corradi, D. *see* Vaglio, A.

D'Errico, N. *see* Veglio, M.
Dalgard, O., Bjøro, K., Hellum, K., Myrvang, B., Bjøro, T., Haug, E. & Bell, H. Thyroid dysfunction during treatment of chronic hepatitis C with interferon alpha: no association with either interferon dosage or efficacy of therapy, 400
Delaval, D. *see* Després, J.-P.
Després, J.-P., Lemieux, I., Salomon, H. & Delaval, D. Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial, 490
Dilek, K. *see* Usta, M.
Diz-Lois, F. *see* de la Iglesia, F.
Djurovic, S. *see* Os, I.
van Doormaal, J.J. *see* van Haelst, P.L.

Efendic, S. *see* Kärvestedt, L.
Eisen, I. *see* Abboud, L.
Ek, A.-C. *see* Hollman, G.
Ekermo, B. *see* Almroth, G.
Eklund, A. *see* Planck, A.
El Salhy, M. *see* Nyhlin, N.
Elving, L.D. *see* Netea, R.T.
Emeis, J.J. *see* Post, M.S.
Eriksson, M. *see* Hollman, G.
Erkelens, D.W. *see* van Venrooij, F.V.
Ersoy, A. *see* Usta, M.

Felmeden, D.C. *see* Lee, K.W.
Ferrozzi, F. *see* Vaglio, A.
Filiz, G. *see* Usta, M.
Fletcher, L.M. & Halliday, J.W. Haemochromatosis: understanding the mechanism of disease and implications for diagnosis and patient management following the recent cloning of novel genes involved in iron metabolism, 181
Forsblad, J. *see* Gottsäter, A.
Fossati, S. *see* Baldini, M.
Fotherby, M.D. & Panayiotou, B.N. Twenty-four hour blood pressure following stroke, 179
Frykman, V. Reply to Jolobe, 365
Fujimura, Y. *see* Orimo, S.

Gallazzi, M. *see* Baldini, M.
Gans, R.O.B. *see* van Haelst, P.L.
Gevers Leuven, J.A. *see* de Beer, F.
Giannini, S. *see* Tedeschi, A.
Gilad, A. *see* Schattner, A.
Giner, V., Muñoz, R. & Redón, J. Risperidone and severe cerivastatin-induced rhabdomyolysis, 177
Gisslén, K., Wieslander, J., Westberg, G. & Herlitz, H. Relationship between anti-neutrophil cytoplasmic antibody determined with conventional binding and the capture assay, and long-term clinical course in vasculitis, 129
Gottsäter, A., Forsblad, J., Mätzsch, T., Persson, K., Ljungcrantz, I., Ohlsson, K. & Lindgärde, F. Interleukin-1 receptor antagonist is detectable in human carotid artery plaques and is related to triglyceride levels and *Chlamydia pneumoniae* IgA antibodies, 61
Grill, V. *see* Kärvestedt, L.
Grobbee, D.E. *see* van Venrooij, F.V.
Grunewald, J. *see* Planck, A.

© 2002 Blackwell Science Ltd

Gullberg, M. *see* Hollman, G.
Güllülü, M. *see* Usta, M.
Gutteberg, T.J. *see* Halvorsen, D.S.

van Haelst, P.L., Asselbergs, F.W., van Doormaal, J.J., Veeger, N.J.G.M., May, J.F., Holvoet, P., Gans, R.O.B. & Cohen Tervaert, J.W. Antineutrophil cytoplasmic antibodies in patients with premature atherosclerosis: prevalence and association with risk factors, 29
Halliday, J.W. *see* Fletcher, L.M.
Halvorsen, D.S., Børvik, T., Njølstad, I., Gutteberg, T.J., Vorland, L.H. & Hansen, J.-B. *Chlamydia pneumoniae* IgA- and IgG antibodies in young survivors of myocardial infarction. A comparison of antibody detection by a microimmunofluorescence test and an enzyme immunoassay, 142
Hansen, J.-B. *see* Halvorsen, D.S.
Hartiala, J. *see* Saaresranta, T.
Hartikainen, J. *see* Nousiainen, T.
Haug, E. *see* Dalgard, O.
Havekes, L.M. *see* de Beer, F.
Hedbäck, G. & Odén, A.S. Cardiovascular disease, hypertension and renal function in primary hyperparathyroidism, 476
Hedblad, B. *see* Norinder, A.
Heise, T. & Sawicki, P.T. Does insulin preserve β-cell function in type 2 diabetes? 283
Hellum, K. *see* Dalgard, O.
Hendriks, D.F. *see* Post, M.S.
Herlitz, H. *see* Gisslén, K.
Herlitz, J. *see* Lundstam, U.
Herlitz, J., Karlson, B.W., Sjölin, M. & Lindqvist, J. Ten-year mortality for patients discharged after hospitalization for chest pain or other symptoms raising suspicion of acute myocardial infarction in relation to hospital discharge diagnosis, 526
Hetta, J. *see* Mallon, L.
Hiatt, W.R. Preventing atherothrombotic events in peripheral arterial disease: the use of antiplatelet therapy, 193
Hilsted, K.L. *see* Madsen, S.M.
Hir, J. *see* Abboud, L.
Hoffmann, J.C., Pistorius, G., Müller, P. & Zeitz, M. Unusual case of a large mideosophageal diverticulum mimicking unstable angina pectoris, 355
Hollman, G., Gullberg, M., Ek, A.-C., Eriksson, M. & Olsson, A.G. Quality of life in patients with familial hypercholesterolaemia, 331
Holm, S. *see* Madsen, S.M.
Holvoet, P. *see* van Haelst, P.L.
Holzmann, M., Olsson, A., Johansson, J. & Jensen-Urstad, M. Left ventricular diastolic function is related to glucose in a middle-aged population, 415
Hoogerbrugge, N. *see* de Beer, F.
Hurt-Camejo, E. *see* Wiklund, O.

de la Iglesia, F., Valiño, P., Pita, S., Ramos, V., Pellicer, C., Nicolás, R. & Diz-Lois, F. Factors predicting a hospital stay of over 3 days in patients with acute exacerbation of chronic obstructive pulmonary disease, 500
Ikäheimo, M. *see* Karvonen, J.
Irjala, K. *see* Saaresranta, T.
Ishizashi, H. *see* Orimo, S.
Ito, Y. *see* Yamakawa, T.

Jantunen, E. *see* Nousiainen, T.
Jensen-Urstad, M. *see* Holzmann, M.
Jiménez, J. *see* Peña, R.
Johansson, J. *see* Holzmann, M.
Johansson, P., Andréasson, B., Safai-Kutti, S., Rhedin, C., Vilén, L., Väärt, J. & Kutti, J. On the diagnosis of polycythaemia vera as assessed in the health and medical care in the Västra Götaland region, Sweden, 348
Jolobe, O.M.P. Asymptomatic versus symptomatic persistent atrial fibrillation: clinical and noninvasive characteristics, 363
Jolobe, O.M.P. The yield of a diagnostic hospital dyspnoea clinic for the primary care section, 366

Kaessmann, H & Pääbo, S. The genetical history of humans and the great apes, 1
Kahan, T. *see* Björholt, I.
Kampmann, K. *see* Madsen, S.M.
Karlson, B.W. *see* Herlitz, J.
Karlsson, T. *see* Lundstam, U.
Kärvestedt, L., Andersson, G., Efendic, S. & Grill, V. A rapid increase in β-cell function by multiple insulin injections in type 2 diabetic patients is not further enhanced by prolonging treatment, 307
Karvonen, J., Kauma, H., Kervinen, K., Rantala, M., Ikäheimo, M., Päivänsalo, M., Savolainen, M.J. & Kesäniemi, Y.A. Endothelial nitric oxide synthase gene Glu298Asp polymorphism and blood pressure, left ventricular mass and carotid artery atherosclerosis in a population-based cohort, 102
Katzman, P. *see* Löndahl, M.
Kauma, H. *see* Karvonen, J.
Keber, I. *see* Sebestjen, M.
Kenemans, P. *see* Post, M.S.
Kervinen, K. *see* Karvonen, J.
Kesäniemi, Y.A. *see* Karvonen, J.
Koskenvuo, M. *see* Marniemi, J.
Kronholm, E. *see* Marniemi, J.
Kuper, H., Adami, H.-O. & Boffetta, P. Tobacco use, cancer causation and public health impact, 455
Kutti, J. *see* Johansson, P.

Lagiou, P. *see* Tamimi, R.M.
Lahoz, C. *see* Peña, R.
Lee, K.W., Felmeden, D.C. & Lip, G.Y.H. Statins and the assessment of endothelial function, 452
Lemieux, I. *see* Després, J.-P.
Leonardi, P. *see* Baldini, M.
Leurs, J.R. *see* Post, M.S.
Lindén, T. *see* Lundstam, U.
Lindgärde, F. *see* Gottsäter, A.
Lindmark, H. *see* Svensson, L.
Lindqvist, J. *see* Herlitz, J.
Lindqvist, P., Bengtsson, C., Lissner, L. & Björkelund, C. Cholesterol and triglyceride concentration as risk factors for myocardial infarction and death in women, with special reference to influence of age, 484
Lip, G.Y.H. *see* Lee, K.W.
Lissner, L. *see* Lindqvist, P.
Ljungcrantz, I. *see* Gottsäter, A.
Ljungdahl, L. *see* Löndahl, M.
Löndahl, M., Katzman, P., Nilsson, A., Ljungdahl, L. & Prutz, K.-G. Cardiovascular prevention before admission reduces mortality following acute myocardial infarction in patients with diabetes, 325
López-Pastor, A. *see* Peña, R.
Lundberg, V., Wikström, B., Boström, S. & Asplund, K. Exploring sex differences in case fatality in acute myocardial infarction or coronary death events in the northern Sweden MONICA Project, 235
Lundstam, U., Herlitz, J., Karlsson, T., Lindén, T. & Wiklund, O. Serum lipids, lipoprotein(a) level, and apolipoprotein(a) isoforms as prognostic markers in patients with coronary heart disease, 111
Lutterman, J.A. *see* Netea, R.T.

Macchia, G. *see* Veglio, M.
Madsen, S.M., Mirza, M.R., Holm, S., Hilsted, K.L., Kampmann, K. & Riis, P. Attitudes towards clinical research amongst participants and nonparticipants, 156
Mallon, L., Broman, J.-E. & Hetta, J. Sleep complaints predict coronary artery disease mortality in males: a 12-year follow-up study of a middle-aged Swedish population, 207
Maloisel, F. *see* Andrès, E.
Manenti, L. *see* Vaglio, A.
Månsson, A.-S. *see* Almroth, G.
Markiewicz, W. *see* Abboud, L.
Marniemi, J., Kronholm, E., Aunola, S., Toikka, T., Mattlar, C.-E., Koskenvuo, M. & Rönnemaa, T. Visceral fat and psychosocial stress in identical twins discordant for obesity, 35
Massari, F.M. *see* Tedeschi, A.
Matsumoto, M. *see* Orimo, S.
Mattlar, C.-E. *see* Marniemi, J.
Mattsson Hultén, L. *see* Svensson, L.
Mattsson-Hultén, L. *see* Wiklund, O.
Mätzsch, T. *see* Gottsäter, A.
May, J.F. *see* van Haelst, P.L.
Meyer, H.E. *see* Yli-Jama, P.
Mirza, M.R. *see* Madsen, S.M.
Mohsen, R. *see* Vessby, J.
van der Mooren, M.J. *see* Post, M.S.
Mostaza, J.M. *see* Peña, R.
Müller, P. *see* Hoffmann, J.C.
Muñoz, R. *see* Giner, V.
Myrvang, B. *see* Dalgard, O.

Netea, R.T., Elving, L.D., Lutterman, J.A. & Thien, Th. Body position and blood pressure measurement in patients with diabetes mellitus, 393
Nicolás, R. *see* de la Iglesia, F.
Nilsson, A. *see* Löndahl, M.
Nilsson, J.-Å. *see* Norinder, A.
Nilsson, P. *see* Norinder, A.
Njølstad, I. *see* Halvorsen, D.S.
Noel, E. *see* Andrès, E.
Norén, K. *see* Svensson, L.
Norinder, A., Persson, U., Nilsson, P., Nilsson, J.-Å., Hedblad, B. & Berglund, G. Costs for screening, intervention, and hospital treatment generated by the Malmö Preventive Project: a large-scale community screening programme, 44
Nousiainen, T., Vanninen, E., Jantunen, E., Puustinen, J., Remes, J., Rantala, A., Vuolteenaho, O. & Hartikainen, J. Natriuretic peptides during the development of doxorubicin-induced left ventricular diastolic dysfunction, 228
Nyhlin, N., Anan, I., El Salhy, M., Ando, Y. & Suhr, O.B. Reduction of free radical activity in amyloid deposits following liver transplantation for familial amyloidotic polyneuropathy, 136

Odén, A.S. *see* Hedbäck, G.
Ohlsson, B. *see* Svensson, L.
Ohlsson, K. *see* Gottsäter, A.
Olsson, A. *see* Holzmann, M.
Olsson, A.G. *see* Hollman, G.
Olsson, R. Can doxycycline cause polyneuropathy? 361
Orimo, S., Ozawa, E., Yagi, H., Ishizashi, H., Matsumoto, M. & Fujimura, Y. Simple plasma exchange reduced autoantibody to von Willebrand factor-cleaving protease in a Japanese man with ticlopidine-associated thrombotic thrombocytopenic purpura, 280
Orsatti, A. *see* Baldini, M.
Os, I., Djurovic, S., Seljeflot, I. & Berg, K. Transforming growth factor (TGF)-β_1 inversely related to vascular cell adhesion molecule-1 in postmenopausal women with coronary artery disease. A possible mechanism for the putative cardioprotective role of TGF-β_1? 223
Oscarsson, J. *see* Wiklund, O.
Östergren, J. *see* Björholt, I.
Ozawa, E. *see* Orimo, S.
Özbek, S. *see* Usta, M.
Özdemir, B. *see* Usta, M.

Pääbo, S. *see* Kaessmann, H.
Pagano, G.F. *see* Veglio, M.
Päivänsalo, M. *see* Karvonen, J.
Palace, M.R. *see* Vlassara, H.
Palmblad, J. Reply to Andrès *et al.*, 535
Panayiotou, B.N. *see* Fotherby, M.D.
Pedersen, J.I. *see* Yli-Jama, P.
Pellicer, C. *see* de la Iglesia, F.
Peña, R., Lahoz, C., Mostaza, J.M., Jiménez, J., Subirats, E., Pintó, X., Taboada, M., López-Pastor, A. & The Rap Study Group, A. Effect of apoE genotype on the hypolipidaemic response to pravastatin in an outpatient setting, 518
Persson, K. *see* Gottsäter, A.
Persson, U. *see* Norinder, A.
Pintó, X. *see* Peña, R.
Pistorius, G. *see* Hoffmann, J.C.
Pita, S. *see* de la Iglesia, F.
Planck, A., Eklund, A., Yamaguchi, E. & Grunewald, J. Angiotensin-converting enzyme gene polymorphism in relation to HLA-DR in sarcoidosis, 217
Polo, O. *see* Saaresranta, T.
Post, M.S., Hendriks, D.F., van der Mooren, M.J., van Baal, W.M., Leurs, J.R., Emeis, J.J., Kenemans, P. & Stehouwer, C.D.A. Oral oestradiol/trimegestone replacement reduces procarboxypeptidase U (TAFI): a randomized, placebo-controlled, 12-week study in early postmenopausal women, 245
Prutz, K.-G. *see* Löndahl, M.
Puustinen, J. *see* Nousiainen, T.

Ramos, V. *see* de la Iglesia, F.
Rantala, A. *see* Nousiainen, T.
Rantala, M. *see* Karvonen, J.
Redón, J. *see* Giner, V.
Remes, J. *see* Nousiainen, T.
Rhedin, C. *see* Johansson, P.
Riis, P. *see* Madsen, S.M.
Ringstad, J. *see* Yli-Jama, P.
Rönnemaa, T. *see* Marniemi, J.
Rosengren, A., Thelle, D. & Wilhelmsen, L. Parental age and coronary disease in the general male population, 258
Rosmond, R., Bouchard, C. & Björntorp, P. A C-1291G polymorphism in the $_{2A}$-adrenergic receptor gene (*ADRA2A*) promoter is associated with cortisol escape from dexamethasone and elevated glucose levels, 252
Rössner, S. *see* Sharma, A.M.
Rudd, A.G. *see* Bhalla, A.

Saaresranta, T., Uotila, P., Saraste, M., Irjala, K., Hartiala, J. & Polo, O. Effect of medroxyprogesterone on pulmonary arterial pressure, exhaled nitric oxide, ECG and arterial blood gases, 421
Safai-Kutti, S. *see* Johansson, P.
Salomon, H. *see* Després, J.-P.
Santaniemi, M. *see* Ukkola, O.
Saraste, M. *see* Saaresranta, T.
Savolainen, M.J. *see* Karvonen, J.
Sawicki, P.T. *see* Heise, T.
Schattner, A., Gilad, A. & Cohen, J. Systemic granulomatosis and hypercalcaemia following intravesical bacillus Calmette–Guérin immunotherapy, 272

Sebestjen, M., Zegura, B. & Keber, I. Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidemia, 77
Sebestjen, M., Zegura, B. & Keber, I. Statins and the assessment of endothelial function – response to Lee *et al.*, 453
Sekihara, H. *see* Yamakawa, T.
Seljeflot, I. *see* Os, I.
Shadid, S. & Ter Maaten, J.C. Sarcoidosis – a great mimicker, 174
Sharma, A.M. & Rössner, S. Who cares about the obese hypertensive patient? 369
Shoji, A. *see* Yamakawa, T.
Sjölin, M. *see* Herlitz, J.
Smelt, A.H.M. *see* de Beer, F.
Stehouwer, C.D.A. *see* Post, M.S.
Stolk, R.P. *see* van Venrooij, F.V.
Subirats, E. *see* Peña, R.
Suhr, O.B. *see* Nyhlin, N.
Svensson, G. *see* Almroth, G.
Svensson, L., Norén, K., Wiklund, O., Lindmark, H., Ohlsson, B. & Mattsson Hultén, L. Inhibitory effects of *N*-acetylcysteine on scavenger receptor class A expression in human macrophages, 437

Taboada, M. *see* Peña, R.
Tamimi, R.M., Lagiou, P., Adami, H.-O. & Trichopoulos, D. Prospects for chemoprevention of cancer, 286
Tanaka, S.-I. *see* Yamakawa, T.
Tedeschi, A., Airaghi, L., Giannini, S., Ciceri, L. & Massari, F.M. High-dose intravenous immunoglobulin in the treatment of acute myocarditis. A case report and review of the literature, 169
Ter Maaten, J.C. *see* Shadid, S.
The Rap Study Group *see* Peña, R.
Thelle, D. *see* Rosengren, A.
Thien, Th. *see* Netea, R.T.
Toikka, T. *see* Marniemi, J.
Tremblay, A. *see* Ukkola, O.
Trichopoulos, D. *see* Tamimi, R.M.

Ukkola, O. & Santaniemi, M. Protein tyrosine phosphatase 1B: a new target for the treatment of obesity and associated co-morbidities, 467
Ukkola, O., Tremblay, A. & Bouchard, C. Lipoprotein lipase polymorphisms and responses to long-term overfeeding, 429
Uotila, P. *see* Saaresranta, T.
Usta, M., Dilek, K., Ersoy, A., Alper, E., Özbek, S., Özdemir, B., Filiz, G., Yavuz, M., Güllülü, M. & Yurtkuran, M. A family with IgA nephropathy and hereditary lymphoedema praecox, 447

Väärt, J. *see* Johansson, P.
Vaglio, A., Manenti, L., Allegri, L., Ferrozzi, F., Corradi, D. & Buzio, C. ANCA-positive periaortic vasculitis: does it fall within the spectrum of vasculitus? 268
Valiño, P. *see* de la Iglesia, F.
Vanninen, E. *see* Nousiainen, T.
van Vark, L.C. *see* de Beer, F.
Veeger, N.J.G.M. *see* van Haelst, P.L.
Veglio, M., Bruno, G., Borra, M., Macchia, G., Bargero, G., D'Errico, N., Pagano, G.F. & Cavallo-Perin, P. Prevalence of increased QT interval duration and dispersion in type 2 diabetic patients and its relationship with coronary heart disease: a population-based cohort, 317
van Venrooij, F.V., Stolk, R.P., Banga, J.D., Erkelens, D.W. & Grobbee, D.E. Primary and secondary prevention in cardiovascular disease: an old-fashioned concept? 301
Vessby, B. *see* Vessby, J.
Vessby, J., Basu, S., Mohsen, R., Berne, C. & Vessby, B. Oxidative stress and antioxidant status in type 1 diabetes mellitus, 69
Vilén, L. *see* Johansson, P.
Vlassara, H. & Palace, M.R. Diabetes and advanced glycation endproducts, 87
Vorland, L.H. *see* Halvorsen, D.S.
Vuolteenaho, O. *see* Nousiainen, T.

Westberg, G. *see* Gisslén, K.
Widell, A. *see* Almroth, G.
Wieslander, J. *see* Gisslén, K.
Wiklund, O. *see* Lundstam, U.
Wiklund, O. *see* Svensson, L.
Wiklund, O., Mattsson-Hultén, L., Hurt-Camejo, E. & Oscarsson, J. Effects of simvastatin and atorvastatin on inflammation markers in plasma, 338
Wikström, B. *see* Lundberg, V.
Wilhelmsen, L. *see* Rosengren, A.
Wolfe, C.D.A. *see* Bhalla, A.

Yagi, H. *see* Orimo, S.
Yamaguchi, E. *see* Planck, A.
Yamakawa, T., Tanaka, S.-I., Ito, Y., Shoji, A. & Sekihara, H. Recurrent pneumonia with unconsciousness, 278
Yavuz, M. *see* Usta, M.
Yli-Jama, P., Meyer, H.E., Ringstad, J. & Pedersen, J.I. Serum free fatty acid pattern and risk of myocardial infarction: a case-control study, 19
Yurtkuran, M. *see* Usta, M.

Zegura, B. *see* Sebestjen, M.
Zegura, B. *see* Sebestjen, M.
Zeitz, M. *see* Hoffmann, J.C.

Journal of Internal Medicine 2002; **251**: 540–541

Keyword index

absolute risk, 301
acute myocardial infarction, 235
adaptation, 331
adenosine diphosphate (ADP) receptor antagonists, 193
adrenergic receptor, 252
advanced glycation endproducts (AGE), 87
age, 484
amyloidosis, 136
angina, 53
angina pectoris, 355
angiotensin-converting enzyme gene polymorphism, 217
anti-inflammatories, 286
anti-neutrophil cytoplasmic antibody, 29, 129, 268
antioestrogens, 286
antioxidants, 69, 286
antiplatelet therapy, 193
anxiety, 331
apolipoprotein E, 518
arterial vasoreactivity, 77
asprin, 193
atherosclerosis, 102, 193
atorvastatin, 338, 490
autoimmunity, 29

blood pressure, 252

cancer, 286, 455
carcinogenesis, 455
cardiovascular, 44
cardiovascular disease(s), 111, 193, 476, 508
carotid artery stenosis, 61
case fatality, 235
cerivastatin, 77
chemoprevention, 286
Chlamydia pneumoniae, 61
Chlamydia pneumoniae antibodies, 142
cholesterol, 518
chronic obstructive pulmonary disease, 500
combined hyperlipidaemia, 77
coronary artery disease, 207, 325
coronary death, 235
coronary disease, 19, 53, 207, 223, 235, 258, 317, 325, 490
coronary heart disease, 223, 317, 490
cortisol, 35, 252
cost analysis, 45
cost benefit analysis, 508
C-peptide glucagon test, 307
CRP, 338
cyclophosphamide, 268

DAN sequence variation, 1
depression, 207
diabetes, 87
diabetes mellitus, 69, 325
diabetes – type 2, 307
diabetic neuropathy, 317
diagnosis, 235
diagnostic criteria, 348
dialysis, 119
diastolic, 228
diet-derived agents, 286
differential diagnosis, 355
doxorubicin, 228
dydrogesterone, 245
dyslipidaemia, 490

echocardiography, 228
EIA test, 142
epidemiology, 207
erythropoietin, 348
E-selectin, 223
exercise, 53

familial hypercholesterolaemia, 331
fenofibrate, 77, 490

genes, 252
genetics, 102
glomerulonephritis, 268
great apes, 1

HDL-cholesterol, 490
hepatitis C virus, 119
hereditary, 136
heredity, 258
HFE gene, 181
HLA class II, 217
HOPE, 508
hormone replacement therapy, 148, 245
humans, 1
hypercalcaemia, 476
hyperglycaemia, 307
hyperparathyroidism, 476
hypertension, 102, 476

ICAM-1, 223, 338
identical twins, 35
IL-6, 338
inflammation, 29
insomnia, 207
insulin resistance, 467
insulin secretion, 307
insulin sensitivity, 307
insulin treatment, 307
interleukin-1 receptor antagonist, 61
interleukin-1β, 61
intestinal iron absorption, 181
intravenous immunoglobulin, 169
iron overload, 181
isoforms, 111
isoprostanes, 69

length of stay, 500
lipid peroxidation, 69
lipoprotein(a), 111
lipoproteins, 111, 148
liver, 136, 181
logistic regression, 500
longevity, 258

medical ethics, 156
micoscopic polyarteritis, 129
midoesophageal diverticulum, 355
MIF test, 142
molecular evolution, 1
mortality, 53, 111, 207, 325, 484, 526
myocardial infarction, 53, 19, 325, 484, 526
myocardial ischaemia, 526
myocarditis, 169

natriuretic peptides, 228
neuropathic oxidative stress, 136
nitric oxide, 102
nonesterified fatty acids, 19
noradrenaline, 35

obesity, 35, 467
oestradiol, 245
omega-3 fatty acids, 19
outpatient, 518

patient recruitment, 156
peripheral artery disease, 193
personal health, 331
phospholipase A2, 338
polycythaemia vera, 348
polymerase chain reaction (PCR), 119
polymorphism, 252
polyunsaturated fatty acids, 19
population study, 258
postmenopausal women, 223
pravastatin, 518
premature atherosclerosis, 29
prevention, 45, 325
primary hyperparathyroidism, 476
primary prevention, 301
procarboxypeptidase U, 245
prognosis, 217, 526
prospective studies, 508
protein tyrosine phosphatase 1B, 467
proteinase 3, 129
psychosocial stress, 35

QT interval, 317
quality of life, 331

ramipril, 508
randomized controlled trials, 156
recombinant immunoblot assay, 119
red cell mass, 348
renal disease, 129
renal function, 476
research ethics, 156
resection, 355
retroperitoneal fibrosis, 268
risk factors, 325

sarcoidosis, 217
screening programme, 45
secondary prevention, 301
seroprevalence, 142
serum amyloid, 338
serum free fatty acids, 19
serum lipids, 484
sex, 235
Short Stay Medical Unit, 500
simvastatin, 338
smoking, 455, 484
spleen size, 348

© 2002 Blackwell Science Ltd

study prospective, 207
survey, 317
survival, 53
systolic, 228

thrombin-activatable fibrinolysis inhibitor, 245
tibolone, 148
tobacco, 455
transforming growth factor-β_1, 223
transmission, 119
transthyretin, 136
treatment, 235
trial participation, 156
triglycerides, 61, 518
trimegestone, 245
transplantation, 136
type 2 diabetes, 307
type III hyperlipoproteinemia, 148

vasa-vasorum, 268
vasculitis, 268
VCAM-1, 223
visceral fat, 35

Wegener's granulomatosis, 129
women, 111, 484